EHA 2024 – In8bio bets on a registrational plan
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
The group is keeping faith with the novel target KLK2.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.